Regulatory Challenges and Concerns in the Acquisition of Grail

This chapter examines the acquisition of Grail by Illumina and the subsequent regulatory challenges, including the FTC's order for divestment due to anti-competitiveness concerns. The speaker shares their views on the politicization of the regulatory system and the lack of alignment between FTC and EU authorities. They also discuss the potential impact of Illumina's dominant position in DNA sequencing on clinical diagnostic applications.